ArticlesArchiveAboutEditorial BoardAuthor Guidelines
Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Ghada Ezzat Eladawei, Sheref Mohamed El-Taher
Background and objective : During routine follow up, there is no specific predictor to ascertain relapse after standard first line chemotherapy in diffuse large cell lymphoma. Therefore, this study was designed to assess the prognostic significance of the rat…
Liuniu Xiao, Li Zhu, Yingming Chen, Zhenlin Hou, Lingwei Jia, Junbo Hu, Yongdong Feng
Background: For Stage II/III rectal cancer patients, curative resection is the primary treatment, prescribing of postoperative adjuvant chemotherapy (PAC) is regarded as a standard therapy. The interval between surgery and the initiation of PAC is usually wit…
Salem Al Zoghby, K. Keriakos, Saad El Daou, J. Darido
Leiomyoma is a benign tumour composed mainly of smooth muscle cells. It contains varying amount of fibrous connective tissue s . Parasitic leiomyoma is a rare manifestation of uterine leiomyoma defined as a pedunculated subserosal fibroid that undergoes torsi…
Tamás Kullmann, Kofi Agyemang-Prempeh, Adél Ambrus, Gabriella Herodek, Balázs Hillier, Károly Kocsis, Ilona Laszip, Mária Mák, Tamás Pintér, István Sipőcz
Ba ckground: Standard adjuvant or neo-adjuvant chemotherapy of primary breast cancers consists of docetaxel and the combination of anthracyclin-c yclophosphamide in two steps. According to international literature , the neo-adjuvant treatment of triple negati…
Sacha Satram-Hoang, Alisha Stein, Patricia Cortazar, Faiyaz Momin, Carolina Reyes
Background : Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) is the most common biologic subtype of breast cancer. Although adjuvant therapy has demonstrated a survival benefit in clinical trials, its use is poorly u…
Iratxe Arranz Villandiego, Sara Gonzalez Aramberri
There is currently no consensus regarding the management of acute cutaneous reactions emerging from a concurrent treatment of radio-and chemotherapy, the goal of this case study series is to provide scientific evidence based on clinical practice regarding the…
Fauzia F. Naime, 1 1
Immune checkpoint inhibitors have shown to be very effective when treating lung cancer. Nivolumab, a programmed death-1 (PD-1) inhibitor has been approved for the treatment of metastatic non-squamous and squamous NSCLC. Immunotherapy with checkpoint inhibitor…
Mohamed-Alaa-Eldeen H. Mohamed
Purpose: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Most of patients present with advanced disease that cannot be treated with curative or ablative intent. The aim of the study was to assess the therapeutic benefit of concurre…
J. Ferdous, S. Khatun, S. Akhter, S. Chowdhury, S. Pervin, M. Amir, A. Goodman
Objective : This study evaluated the risk factors for pelvic lymph node metastasis in patients with early stage cervical cancer. Material and Methods: A cross sectional study was carried out in the Division of Gynaecologic Oncology at Bangabandhu Sheikh Mujib…
Abdelhamid M. Fouad, Magdy M. Saber, Yahia M. Ismail, Yasser A. Sallam, Tarek M. Shouman, Reham A. A. Elshimy, Ahmed Abo Gabal
Introduction: Docetaxel, Cisplatin and 5-Fluorouracil (DPF) became the standard induction chemotherapy in advanced Head and Neck Cancer (HNC) but associated with high toxicity rate. Several studies reported higher response rates with better tolerability when…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).